A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

What Was Tested

This registered phase 3 trial tested Orforglipron (Foundayo, non-peptide).

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2.

Participation in the study will last about 74 weeks.

It had four arms (groups): Orforglipron (GZT1) (experimental), Placebo (GZT1) (placebo comparator), Orforglipron (GZT2) (experimental) and Placebo (GZT2) (placebo comparator).

Participants will receive orforglipron orally.

Participants will receive placebo orally.

Participants will receive orforglipron orally.

The registry classes the interventions as drug.

Who Took Part

The registry lists 800 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening. Have tried at least once to lose weight through diet but were unsuccessful. Have osteoarthritis of the knee and at least one of the following conditions:. Be over 50 years old. Have morning knee stiffness that lasts about 30 minutes.

The full record lists 6 inclusion and 6 exclusion criteria; among the exclusions: have gained or lost more than 11 pounds within 90 days prior to screening; have had a surgery for obesity or plan to have one in the next 18 months; have an active knee infection.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

Because people in this Orforglipron (Foundayo, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Orforglipron (Foundayo, non-peptide) study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2025-09-15 with completion listed for 2028-04.

It ran at 88 sites in United States (26), China (16), Germany (13), Japan (11), Canada (8) and Spain (8).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score (time frame: Baseline, Week 72).

It also tracked 17 secondary outcomes, for example Change from Baseline in the WOMAC Physical Function Subscale Score, Percent Change from Baseline in Body Weight, Change from Baseline in 36-item, Short-Form Health Survey, version 2 (SF-36v2) Acute Form Physical Functioning Domain Score, Change from Baseline in Distance Walked During the 6-Minute Walk Test, Percent Change from Baseline in High-Sensitivity, C-reactive Protein (hsCRP) and Change from Baseline in Waist Circumference.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Orforglipron (Foundayo, non-peptide) in 800 people.

With 800 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.